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MicroRNAs (miRNAs) are small RNAs regulating gene expression post-transcriptionally.
Recent studies demonstrated that miRNAs are involved in the development of congenital
heart defects (CHD). In this study, we aimed at identifying the specific patterns of miRNAs in
blood of monozygotic twin pairs discordant for CHD and to assess whether miRNAs might
be involved in the development or reflect the consequences of CHD.
Methods
miRNA microarray analysis and Real-Time Quantitative PCR (RT-qPCR) were employed to
determine the miRNA abundance level from 12 monozygotic twins discordant for CHD and
their non-CHD co-twins (n = 12). Enrichment analyses of altered miRNAs were performed
using bioinformatics tools.
Results
Compared with non-CHD co-twins, profiling analysis indicated 34 miRNAs with a significant
difference in abundance level (p<0.05, fold change� 1.3), of which 11 miRNAs were up-
regulated and 23 miRNAs were down-regulated. Seven miRNAs were validated with RT-
qPCR including miR-511-3p, miR-1306-5p, miR-421, miR-4707-3p, miR-4732-3p, miR-
5189-3p, and miR-890, and the results were consistent with microarray analysis. Five miR-
NAs namely miR-511-3p, miR-1306-5p, miR-4732-3p, miR-5189-3p, and miR-890 were
found to be significantly up-regulated in twins < 10 years old. Bioinformatics analysis
showed that the 7 validated miRNAs were involved in phosphatidylinositol signaling, gap
junction signaling, and adrenergic signaling in cardiomyocytes.
Conclusions
Our data show deregulated miRNA abundance levels in the peripheral blood of monozygotic
twins discordant for CHD, and identify new candidates for further analysis, which may
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contribute to understanding the development of CHD in the future. Bioinformatics analysis
indicated that the target genes of these miRNAs are likely involved in signaling and commu-
nication of cardiomyocytes.
Introduction
During the last two centuries, the percentage of twin births in the general population has
increased. Assisted reproductive technologies are likely responsible for the increased number
of twin births because multiple embryos are implanted [1, 2]. In general, the rate of congenital
anomalies is higher in twins compared with singletons [3–5], especially the discordance for
cardiovascular anomalies [3, 6]. Moreover, it has been shown that the risk of congenital anom-
alies among twins that share a placenta (i.e. monochorionic twins, who are almost uniformly
monozygotic) is nearly twice as high compared to twins that do not share a placenta (i.e.
dichorionic, mostly dizygotic twins) [3].
Congenital heart defect (CHD) is one of the most common types of birth defects, with a
neonatal incidence of 0.8–1.0% [7]. CHD includes a broad range of heart development malfor-
mations that begin early in fetal development such as atrial septal defects (ASD), ventricular
septal defects (VSD), Tetralogy of Fallot [8], and transposition of the great arteries [9]. The
clinical spectrum of congenital heart defects is broad from mild to severe and complex, such as
ASDs and VSDs being usually clinically asymptomatic until school age or early adulthood,
while others such as hypoplastic left heart syndrome, tetralogy of Fallot, and transposition of
great arteries lead to cyanosis and inadequate pulmonary and systemic perfusion if adequate
surgical treatment is not performed [7]. Accordingly, the clinical course may range from spon-
taneous recovery up to a life-long medical treatment with multiple interventional and surgical
procedures, often already starting in the early postnatal age.
Over the last years, it has become apparent that a wide variety of protein-coding genes and
other molecules such as non-coding RNAs are involved in maintaining a restricted and spe-
cific pattern of gene expression in the heart [10]. MiRNAs are a class of non-coding RNAs of
approximately 22 nucleotides in length that regulate gene expression post-transcriptionally via
a sequence-specific interaction with the 3’ UTR of target mRNAs, resulting in inhibition of
translation and/or mRNA degradation [11]. Since a non-CHD co-twin in a CHD-discordant
monozygotic twin pair provides a well-matched control, we hypothesized that alterations in
miRNA abundance level might contribute to the discordance in monozygotic twin pairs with
CHDs. To test this hypothesis, we investigated twelve monozygotic twin pairs which were dis-
cordant for CHD using high-throughput microarray screening and RT-qPCR validation
analysis.
Methods
Patients and sample collection
The study was conducted following the Declaration of Helsinki and was approved by the
locally appointed ethics committee (Ethik-Kommission Landesärztekammer des Saarlandes,
No. 178/14). A total of 12 twin pairs (14 females, 10 males) with a mean age of 11.00 ± 5.53
years were enrolled in the study (Table 1). Only twin pairs in which one co-twin was diag-
nosed with CHD and the other co-twin was healthy (non-CHD) were included in the study.
None of the patients at the time of blood collection was diagnosed with heart failure and all
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included twins were asymptomatic without heart failure. The majority had already undergone
corrective, palliative cardiac surgery or therapeutic catheter intervention, while others were
still in follow up because therapeutic approaches were still not necessary. In this study, twins
with ASD and VSD were only considered, when they hemodynamically effective and only
patients with hemodynamically effective PDA, who need interventional closure were also con-
sidered. All twin patients were still under medical treatment and follow up at the Department
of Pediatric Cardiology at the University Hospital of Saarland, Homburg/Saar during data col-
lection. Clinical data were collected from the patient charts and the twins’ parents. Venous
blood from the cubital vein was drawn and 2.5 mL were collected in PAXgeneTM blood tubes
(BD Biosciences, San Jose, CA, USA) and stored at room temperature for 2 hours till complete
lysis of blood cells was achieved before they were stored at -20˚C until RNA including miRNA
isolation. Another 2.5 mL blood sample was collected from each included subject for the DNA
typing. All samples were collected and processed at the Department of Pediatric Cardiology
and the Institute for Human Genetics at the University Hospital of Saarland, Germany. Sam-
ples were analyzed according to standard operating procedures after all participants or their
legal guardians had given their written informed consent.
Table 1. Characteristics of the monozygotic twins included in the study.
Code Age Gender CHD
HOAZ_1003 7 Male AVSD
HOAZ_1004 7 Male non-CHD
HOAZ_1005 5 Male MI, LVOTO, PDA, AS
HOAZ_1006 5 Male non-CHD
HOAZ_1010 17 Female PDA
HOAZ_1011 17 Female non-CHD
HOAZ_1012 11 Male DILV, VSD
HOAZ_1013 11 Male non-CHD
HOAZ_1015 5 Female CoA
HOAZ_1016 5 Female non-CHD
HOAZ_1019 5 Female LPA-Stenosis
HOAZ_1020 5 Female non-CHD
HOAZ_1023 10 Male ASD II
HOAZ_1024 10 Male non-CHD
HOAZ_1027 19 Female non-CHD
HOAZ_1028 19 Female Coronary fistula
HOAZ_1033 12 Female TOF, VSD, ASD
HOAZ_1034 12 Female non-CHD
HOAZ_1035 9 Female VSD
HOAZ_1036 9 Female non-CHD
HOAZ_1039 22 Female non-CHD
HOAZ_1040 22 Female mid-aortic syndrome
HOAZ_1041 10 Male bicuspid aortic valve
HOAZ_1042 10 Male non-CHD
CHD, congenital heart disease; AVSD, Atrioventricular septal defect; MI, Mitral insufficiency; LVOTO, Left
ventricular Outflow Tract Obstruction; PDA, Patent Ductus arteriosus; AS, Aortic stenosis; TGA, Transposition of
the great arteries; ASD, Atrial septal defect; VSD, Ventricular septal defect; TOF, Tetralogy of Fallot; DILV, Double
inlet left ventricle; CoA, Coarctation of the aorta; LPA-Stenosis, Left pulmonary artery stenosis; PS, Pulmonary
stenosis
https://doi.org/10.1371/journal.pone.0226164.t001
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Zygosity determination
Zygosity of the twin pairs was tested using the AmpFιSTR1 Identifiler™/NGM SElect™ PCR
Amplification Kit (Applied Biosystems, Foster City, CA, USA) at the Institute of Forensic
Medicine, Charité University of Berlin (S1 Table). Briefly, genomic DNA was extracted from
the blood of each participant using the ReliaPrep™ Large Volume HT gDNA Isolation System
(Promega, Mannheim, Germany). The DNA integrity, purity, and concentration were evalu-
ated by agarose gel (0.8%) electrophoresis and by spectrophotometry at the wavelengths of 230
nm, 260 nm, and 280 nm. Zygosity of the twin pairs was confirmed by typing all included
twins with the 22 Short Tandem Repeat loci namely D10S1248, vWA, D16S539, D2S1338,
D8S1179, D21S11, D18S51, D22S1045, D19S433, TH01, FGA, D2S441, D3S1358, D1S1656,
D12S391, SE33, D7S820, CSF1PO, D13S317, TPOX and D5S818. PCR products were sepa-
rated on an ABI capillary sequencer and evaluated using GeneMapper ID Software (Applied
Biosystems).
Isolation of total RNA, including miRNAs
Total RNA, including miRNAs of all patients and their non-CHD co-twins, was extracted with
the PAXgene miRNA blood kit using the QIAcube™ automated isolation instrument according
to the manufacturer’s instructions (Qiagen, Hilden, Germany). The concentration and purity
of the samples were measured using the NanoDrop ND-1000 Spectrophotometer (Thermo
Fisher Scientific, Massachusetts, USA). The RNA integrity was assessed with an Agilent 2100
Bioanalyzer using RNA 6000 Nano kit (Agilent Technologies, California, USA). DNase I
(Thermo Fisher Scientific, Massachusetts, USA) treatment was carried out according to the
manufacturer’s instructions to remove any DNA contamination. Conventional PCR with exon
spanning primers for Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed
to exclude residual DNA in the samples as previously described [12].
miRNA profiling
miRNA profiling analysis of 12 twin pairs (24 individuals) was carried out using SurePrint G3
Human miRNA, 8X60K microarray, covering 2549 human miRNAs (Sanger miRBase release
21) (Agilent Technologies). These microarrays contain ~20 replicates for each probe comple-
ment to each of the 2549 mature miRNAs of miRBase v21. These probes act in concert to mea-
sure the miRNA of interest, and the data are combined later during software analysis. All
probes are randomly distributed on the array, and cross-hybridization is prevented by the
addition of a G residue and a hairpin at the 50-end of the probe. All procedures were carried
out as previously described [13, 14]. In brief, a total of 100 ng total RNA from each sample was
dephosphorylated by incubation with calf intestinal phosphatase at 37˚C for 30 minutes and
denatured with the use of 100% dimethyl sulfoxide at 100˚C for 7 minutes. Samples were
labeled with pCp-Cy3 with the use of T4 ligase at 16˚C incubation for 2 hours. Each labeled
RNA sample was hybridized onto an individual sub-array of the 8×60K format Agilent
miRNA microarray slide. Then the microarrays were loaded and incubated at 55˚C for 20
hours with rotation. After two washing steps, the arrays were dried and scanned using the Agi-
lent Microarray Scanner at 3 microns in double path mode. Data was acquired using Agilent
AGW Feature Extraction software version 10.10.11 (Agilent Technologies).
Analysis of miRNAs by RT-qPCR
RT-qPCR validation analysis was performed according to the manufacturer’s instructions
using the miScript PCR System (Qiagen). Complementary DNA (cDNA) was generated by
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reverse transcription of 200 ng of total RNA using the miScript RT II Kit (Qiagen). Briefly, 200
ng of total RNA containing miRNAs was mixed with 4 μL miScript HiSpec Buffer, 2 μL nucleic
mix, 2 μL miScript Reverse Transcriptase mix and PCR grade water to a final volume of 20 μL.
Following the reverse transcription reaction, the cDNA was diluted 1:10. Two-μL of diluted
cDNA was mixed with 10 μL miScript SYBR Green PCR Master Mix, 2 μL miScript Universal
Primer, 2 μL miScript Primer Assay for eleven miRNAs (miR-511-3p, miR-1306-5p, miR-421,
miR-134-3p, miR-4707-3p, miR-4732-3p, miR-1281, miR-6511a-3p, miR-5189-3p, miR-943,
miR-890) and RNU6B snRNA as an endogenous control (Qiagen) in a total volume of 20 μL.
All RT-qPCR experiments were performed using the QIAgility™ automated PCR setup robot
(Qiagen) before performing RT-qPCR analysis in the StepOnePlus™ Real-Time PCR system
(Applied Biosystems) as previously described [15]. The melting curve analysis was used to con-
trol the specificity of RT-qPCR products. The specificity of amplicons was further confirmed
by agarose gel electrophoresis.
Statistical analysis
R statistical environment v.2.14.2 was used to analyze the differences in miRNA abundance
level in patients and their non-CHD co-twins. The intensity values of miRNAs were extracted
with the use of Agilent Feature Extraction image analysis software. To compute the total abun-
dance level per miRNA and sample, we summed up the gTotalProbeSignals. A quantile nor-
malization method was applied to normalize abundance levels across the arrays with the use of
the preprocess Core package of the R programming language. The significance level of each
miRNA was then analyzed by applying student t-test and area under the receiver operating
characteristic curve (AUC) values for each miRNA were computed. For validation of the
microarray results, we used the relative quantitative method of 2−ΔΔCt [16] to measure the dif-
ferences of miRNA abundance between the two tested groups i.e. patients with CHD and their
non-CHD co-twins. Results were statistically analyzed with GraphPad Prism (version 7.04,
GraphPad Software Inc., San Diego, CA) and presented as mean ± SD. Statistically significant
differences in the level of each miRNA between the two paired twins were assessed by paired t-
test. P-values <0.05 were considered statistically significant.
Target prediction and functional analysis
Enriched KEGG pathway analyses were performed using DIANA-miRPath v.3.0 software
which utilizes predicted miRNA targets (in the coding sequence (CDS) or 3`-UTR regions)
provided by DIANA-microT-CDS algorithm [17]. Targets of miRNAs with a threshold of
more than 0.8 were selected. Only KEGG pathways with P-values <0.05 and a false discovery
rate (FDR) <0.05 were retained. The effect of miRNAs on target genes and networks has been
evaluated using miRTargetLink software [18].
Results
Differentially abundant miRNAs
We found 208 (8.16%) miRNAs with a significant difference in abundance level when compar-
ing twins with CHD to their non-CHD co-twins (S2 Table) (p<0.05). When considering the
differentially abundant miRNAs a fold change of� 1.3 in the twins with CHD compared to
their non-CHD co-twins, 34 miRNAs (1.33%) were found to be differentially abundant, of
which 11 miRNAs were up-regulated and 23 miRNAs were down (Table 2) (P<0.05). As
shown in Table 2, the mean fold change of the up-regulated miRNAs was 1.52 ± 0.30, whereas
the mean fold change of the down-regulated was 0.71 ± 0.05. Eleven miRNAs were chosen for
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further validation by RT-qPCR based on their differential abundance level as determined by
microarray between twins with CHD and their non-CHD co-twins and based on their known
associations with cardiovascular diseases. In detail, we selected four miRNAs with highest
(miR-5189-3p, miR-4707-3p, miR-1306-5p, and miR-4732-3p) and three moderate (miR-511-
3p, miR-890, and miR-421) fold change among the up-regulated miRNAs and two miRNAs
with highest (miR-943 and miR-6511a-3p) and moderate (miR-1281 and miR-134-3p) fold
change among the down-regulated miRNAs. In addition, we selected five miRNAs (miR-
1306-5p, miR-511-3p, miR-421, miR-1281, and miR-134-3p) with higher and moderate or low
Table 2. Significantly abundant miRNAs in the blood of monozygotic twin pairs with CHD (n = 12) compared to their non-CHD co-twins (n = 12) as determined
by microarray analysis (P<0.05).
miRNAs Median non-CHD Median CHD STDV non-CHD STDV CHD Fold Change Regulation P-value AUC
miR-5189-3p 4.33 10.39 3.48 4.01 2.38 Up 0.0176 0.77
miR-4707-3p 2.64 4.42 1.37 1.81 1.67 Up 0.0208 0.66
miR-1306-5p 4.73 7.63 2.30 2.81 1.61 Up 0.0206 0.67
miR-4732-3p 34.81 53.13 25.02 36.38 1.52 Up 0.0102 0.64
miR-3605-3p 3.62 5.22 1.19 1.42 1.45 Up 0.0447 0.66
miR-550b-2-5p 5.62 7.69 2.22 2.15 1.37 Up 0.0228 0.65
miR-511-3p 0.83 1.13 0.23 0.29 1.35 Up 0.0329 0.73
miR-890 0.87 1.17 0.28 0.18 1.35 Up 0.0309 0.81
miR-671-5p 2.47 3.31 0.95 1.16 1.33 Up 0.0385 0.69
miR-128-1-5p 2.10 2.82 0.81 0.73 1.35 Up 0.0483 0.72
miR-421 2.54 3.35 0.76 0.67 1.32 Up 0.0193 0.72
miR-7109-3p 4.28 2.37 2.27 1.63 0.56 Down 0.0278 0.38
miR-943 2.07 1.28 0.64 0.42 0.62 Down 0.0038 0.24
miR-6511a-3p 4.38 2.76 4.38 1.52 0.63 Down 0.0323 0.30
miR-6735-3p 2.73 1.81 1.66 0.72 0.67 Down 0.0329 0.24
miR-6787-3p 3.15 2.12 2.37 1.41 0.67 Down 0.0133 0.35
miR-6877-3p 4.13 2.82 1.30 0.51 0.68 Down 0.0090 0.23
miR-4296 1.50 1.04 0.44 0.51 0.69 Down 0.0459 0.36
miR-1281 7.78 5.35 16.10 9.02 0.69 Down 0.0299 0.33
miR-3677-3p 1.18 0.84 0.40 0.19 0.71 Down 0.0083 0.24
miR-4763-5p 3.68 2.66 1.71 1.05 0.72 Down 0.0360 0.36
miR-7106-3p 2.40 1.76 0.96 0.50 0.73 Down 0.0086 0.23
miR-6789-3p 2.54 1.85 0.91 0.63 0.73 Down 0.0366 0.35
miR-1825 7.09 5.19 13.02 6.84 0.73 Down 0.0481 0.35
miR-134-3p 2.43 1.78 0.56 0.36 0.74 Down 0.0064 0.26
miR-1343-3p 2.42 1.80 0.89 0.71 0.74 Down 0.0307 0.33
miR-6727-3p 2.08 1.55 0.57 0.66 0.75 Down 0.0033 0.29
miR-6736-3p 3.14 2.34 0.84 0.56 0.75 Down 0.0083 0.30
miR-8075 1.59 1.20 0.57 0.29 0.75 Down 0.0241 0.28
miR-3714 2.66 2.02 1.02 0.63 0.76 Down 0.0043 0.21
miR-6879-3p 2.66 2.02 1.04 0.79 0.76 Down 0.0250 0.38
miR-675-3p 2.42 1.84 0.67 0.69 0.76 Down 0.0292 0.27
miR-6743-3p 5.02 3.81 13.28 8.08 0.76 Down 0.0312 0.37
miR-4800-3p 2.24 1.72 0.60 0.43 0.76 Down 0.0158 0.32
Each value represents the median abundance value of each tested group ± standard deviation (STDV). CHD, Congenital heart defects; AUC, area under the receiver
operating characteristic curve.
https://doi.org/10.1371/journal.pone.0226164.t002
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abundance levels based on the array analysis and with known association with cardiac patholo-
gies, vascular remodeling, aortic aneurysm and its related process [14, 15, 19–25].
Validation of candidate miRNAs by RT-qPCR
Using RT-qPCR, the relative abundance level of 11 miRNAs was confirmed in the same sam-
ples, which have been used for the microarray experiments. As shown in Fig 1, RT-qPCR
showed the same direction of abundance changes as the microarray analysis for 7 out of 11
used miRNAs when comparing the samples from patients with CHD to their non-CHD co-
twins (miR-511-3p, miR-1306-5p, miR-421, miR-4707-3p, miR-4732-3p, miR-5189-3p, and
miR-890). Significant changes in abundance were confirmed for these seven up-regulated
miRNAs (p< 0.05). No significant differences in abundance were found for two miRNAs,
namely miR 6511a-3p and miR-943 (p = 0.1309 and 0.1639, respectively). In addition, miR-
134-3p and miR-1281 displayed significant changes in abundance in the opposite direction in
RT-qPCR compared to microarray analysis (p = 0.0108 and p = 0.0310, respectively). Next, we
grouped the samples into two groups according to the median age distribution of our patients;
twins younger than 10 years (< 10 years) and twins older than 10 years (� 10 years). As shown
in Fig 2, we found a significant up-regulation for 5 miRNAs including miR-511-3p, miR-
1306-5p, miR-4732-3p, miR-5189-3p, and miR-890 (p< 0.05) in < 10 years group. In� 10
years group, there was no significance in miRNA abundance level when comparing the
patients against their healthy counterparts (Fig 2). MiR-5189-3p showed a 1.97 fold change
when comparing patients�10 years with their healthy co-twins, however, statistical signifi-
cance was marginally missed (p = 0.0863).
Comparative pathway analysis
We used the DIANA-mirPath algorithm to gain insights into the biological pathways of the
miRNAs that showed significant abundance changes between patients with CHD and their
non-CHD co-twins. Based on the seven validated miRNAs by RT-qPCR (miR-511-3p, miR-
1306-5p, miR-421, miR-4707-3p, miR-4732-3p, miR-5189-3p, and miR-890), we identified ten
KEGG pathways that were significantly enriched (p<0.05) for targets of the validated miRNAs.
Fig 1. Validation of differentially abundant miRNAs in the blood of monozygotic twin pairs with CHD (n = 12) compared to their non-CHD co-twins (n = 12) as
determined by RT-qPCR analysis (P< 0.05). Mean ΔCt of each group were considered (lower ΔCt, higher abundance level). RNAU6B as an endogenous control for
normalization, unpaired t-tests and ±standard deviation (STDV) were used to evaluate differences in abundance level. � P� 0.05; �� P� 0.01; ��� P� 0.001.
https://doi.org/10.1371/journal.pone.0226164.g001
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As shown in Table 3, the target genes of the altered miRNAs are involved in signaling trans-
duction pathways, adrenergic signaling in cardiomyocytes, cellular community, and many
other pathways. Using miRTargetLink, the resulting networks are drawn schematically in Fig
3. The strong and weak interactions which were observed between miRNAs and genes are
highlighted in the green’ and blue in the networks, respectively (Fig 3).
Discussion
In this study, we identified altered miRNA abundance levels in monozygotic twins with
CHDs, when compared with their non-CHD co-twins by microarray and RT-qPCR analyses.
miRNA profiling analysis using microarrays indicated 34 miRNAs with differential abundance
levels, of which 11 miRNAs were up-regulated and 23 miRNAs were down-regulated (P
<0.05, fold change�1.3). Using RT-qPCR, 7 miRNAs were validated in the direction of their
abundance changes. Our data indicate that the differential abundance level of these miRNAs
might contribute to the development of CHD and the discordance of CHD in monozygotic
twins. With rare exceptions, CHD is genetically multifactorial rather than purely inheritable
disturbance of prenatal development. Between about embryonic weeks 3 to 5, a delicate con-
certed action of origin and clinical severity gene activities is required to properly perform the
fusion of the heart tubes and the endocardial cushions, the formation of septa, cleavage of aor-
tic and pulmonary trunks and formation of valves [26]. It is therefore well conceivable that
even slight alterations of the intra-uterine microenvironment, e.g., by temporary local distur-
bances of maternal blood supply can cause lasting structural defects of the developing organ,
in spite of the identical genomic composition of monozygotic twins. Thus, discordance for the
development of structural defects in the cardiovascular system among monozygotic twins
reflects the strong exogenous influences on the organogenesis of the fetal heart.
Epigenetic factors play an important role in the regulation of gene expression through mul-
tiple molecular mechanisms including binding of small molecules to specific sites in DNA like
non-coding RNAs (ncRNAs) and miRNAs and serve as ‘volume controls’ that tune-up or
Fig 2. Validation of differentially abundant miRNAs in the blood of monozygotic twin pairs with CHD compared to their healthy co-twins according to age
[10� years (n = 7 twin pairs) and 10< years (n = 5 twin pairs) as determined by RT-qPCR analysis (P< 0.05). Mean ΔCt of each group were considered (lower ΔCt,
higher abundance level). RNAU6B as an endogenous control for normalization, unpaired t-tests and ±standard deviation (STDV) were used to evaluate differences in
abundance level. � P� 0.05; �� P� 0.01; ��� P� 0.001.
https://doi.org/10.1371/journal.pone.0226164.g002
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down a gene’s expression [27]. Further studies, however, should be carried out to evaluate the
effects of miRNAs on epigenetic machinery and the control of miRNA expression by epige-
netic mechanisms in patients of congenital heart and vessel defects. MiRNAs are of eminent
importance for the regulation of gene activities in embryogenesis, in particular for the opening
and closure of the often short windows of time designated for the proliferation and spatial
organization of developing heart muscle, endocardial, and connective tissue cell [26, 28]. A
wide variety of miRNAs are involved in the embryogenesis and development of the heart and
appears likely that CHD conversely alters postnatal expression patterns of multiple miRNAs in
a variable fashion. Alterations of miRNA expression patterns are unlikely a result of hemody-
namic changes and decreased saturation caused by CHD. We postulate that the significant dif-
ference in the abundance of miRNAs in these twins with and without CHD may also be
influenced by the congenital defects and the ongoing tissue remodeling or degeneration of the
developing heart.
In this study, we identified 5 miRNAs with significant up-regulation in monozygotic twins
with CHD <10 years, when compared with their non-CHD co-twins by microarray and RT-
qPCR analysis. A significant up-regulation of miR-1306-5p was found in twins with CHD <10
years compared to non-CHD without CHD. This observation may be related to the accelerated
growth and maturation level in young twins, which is higher during the first 10 years of age,
however, it is premature to draw conclusions about the influence of age on the data. Van
Boven et al. showed that repeatedly measured miR-1306-5p in acute heart failure patients was
positively associated with a composite endpoint of all-cause mortality and re-hospitalization
due to heart failure [23]. It appears likely, that an up-regulation of miR-1306-5p is mainly
Table 3. The KEGG pathways significantly enriched for target genes of validated seven deregulated miRNAs by RT-qPCR analysis in the blood of monozygotic
twin pairs with CHD (n = 12) compared to their non-CHD co-twins (n = 12) as determined by DIANA-mirPath algorithm (P<0.05).
KEGG pathway P-value Gene Name miRNA name
Gap junction (hsa04540) 4.05E-06 NRAS, TUBA1B, GRM5, TUBB6, EGFR, GNAI3, TJP1, PLCB1, TUBA1C,




Biotin metabolism (hsa00780) 4.47E-05 HLCS miR-890










1.33E-02 CAMK2D, PPP2R5E, CALM1, PIK3CB, ATF6B, CACNB4, PPP1CC, PPP2R5D,
GNAI3, PPP2R2D, PPP2R5C, CALM2, ATP2B1, CREB1, PLCB1, SLC8A1,
PRKX, CACNB2, ADCY4, ADRB1, KCNE1
miR-1306-5p, miR-421, miR-890,
miR-511-3p, miR-4732-5p
Dopaminergic synapse (hsa04728) 1.54E-02 CAMK2D, GSK3B, PPP2R5E, CALM1, ATF6B, PPP1CC, PPP2R5D, PPP3CC,
GNAI3, PPP2R2D, PPP2R5C, CALM2, CREB1, MAOB, PLCB1, GNB2, SCN1A,





1.64E-02 PLCD4, CDS2, CALM1, PIK3CB, ITPKB, IPPK, INPP4B, CALM2, PIP4K2A,





1.64E-02 CAMK2D, NRAS, PRKAA2, CALM1, PIK3CB, CACNB4, PPP1CC, ROCK2,
PPP3R1, KCNJ14, CAMKK1, EGFR, PPP3CC, GNAI3, PPP1R12B, CALM2,







1.98E-02 ATF6B, GSR, CREB1, PLCB1, PRKX, TG, ADCY4 miR-421, miR-1306-5p, miR-890
Circadian entrainment (hsa04713) 3.62E-02 CAMK2D, CALM1, GNAI3, CALM2, CREB1, PLCB1, GNB2, GNG7, PRKX,
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linked to the cardiovascular system, which also undergoes maturation and growth in this age.
We found a significant up-regulation of miR-421 by RT-qPCR (Fold change: 2.07, p = 0.0264)
in twins with CHD compared to their non-CHD co-twin. However, microarray analysis
revealed only a marginal up-regulation (Fold change: 1.32, p = 0.0193), which may be associ-
ated with the low sample size of our study. MiR-421 is downregulated in patients with TOF
and heart failure compared to TOF patients without heart failure [14]. Moreover, miR-421 is
involved in mitochondrial fragmentation and cardiomyocyte apoptosis together with E2F1
and Pink1 [24] and regulates angiotensin-converting enzyme 2 (ACE2) expression. Therefore,
miR-421 appears to play a critical role in early cardiac remodeling and a decreased miR-421
expression in twins with CHD in our study may be indicative of heart failure in this cohort.
To the best of our knowledge miR-511-3p, miR-890, and miR-4732-3p, which we found to
be up-regulated in twins with CHD < 10 years of age, miR-5189-3p which was found to be up-
regulated in twins with CHD regardless of age as well as miR-4707-3p which was up-regulated
in twins with CHD in the RT-qPCR analysis, have neither been reported to be deregulated in
association with cardiac disease in general nor between monozygotic twins. Our data show a
differential abundance of these miRNAs in our patients and indicate that these miRNAs may
be associated with the development of CHD in monozygotic twins. So far, these miRNAs have
been poorly characterized and future studies analyzing their function and potential role in the
development of CHD are needed.
Fig 3. Target network of validated seven deregulated miRNAs by RT-qPCR analysis in the blood of monozygotic twin pairs with CHD (n = 12) compared to their
non-CHD co-twins (n = 12) as determined by miRTargetLink algorithm. MiRNAs are shown as brown nodes. Strong and weak interactions were observed between
miRNAs and genes are highlighted in ’’Green’’ and ’’Blue’’ in the resulting networks, respectively.
https://doi.org/10.1371/journal.pone.0226164.g003
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KEGG pathway analysis revealed that the predicted target genes of the 7 validated miRNAs
were involved in phosphatidylinositol signaling, gap junction signaling, and adrenergic signal-
ing in cardiomyocytes among other pathways. Therefore, it appears likely that the pathogenic
role the candidate miRNAs identified in our study play in the development of CHD, is medi-
ated via deregulated signaling and cellular communication in cardiomyocytes.
Study limitations
Limitations of our study are related to the limited sample size and heterogeneity of affected
monocytic twins. Moreover, we had to incorporate CHD of different morphological and clini-
cal types and severity, due to the low incidence of monozygotic twins discordant for CHD.
Since it has been shown that even non-CHD monozygotic twins display a considerable varia-
tion of their miRNA fingerprints [29], we were prepared to encounter a highly complex and
heterogeneous picture. It is a challenge to recruit and assay monozygotic twins and even collect
data for a given phenotype. Relatedly, and critically, the reported miRNAs need to be furtherly
validated in a larger and independent cohort of monozygotic twins to confirm the abundance
level of the identified miRNAs. Furthermore, the precise abundance level and mechanisms
underlying the identified miRNAs should be evaluated in subgroups of uniform diagnosis of
congenital heart defects. Nevertheless, in our study, significant differences in the miRNA
abundance level were found between the affected and non- affected monocytic twins. These
differences may induce several physiological responses in the twins with CHD, which in part is
reflected by changed miRNA abundance levels.
Conclusion
We identified a set of deregulated miRNAs in monozygotic twins with CHD compared to
their non-CHD co-twins. The predicted target genes of these miRNAs are involved in cardio-
myocyte signaling and communication. The alteration of the abundance levels of these miR-
NAs provides new candidates for further analysis, which may contribute to understanding the
development of CHD in the future.
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